Clinical trials: Osteoporosis, Postmenopausal, open to volunteers
Osteoporosis
The Relationship Between Osteoporosis and Sarcopenia Parameters in Postmenopausal Women Under 60
This cross-sectional study will include postmenopausal women under the age of 60 who visited the Physical Medicine and Rehabilitation outpatient clinic at Beylikdüzü State Hospital between June 25 and July 25, 2025.
- Trial name
- NCT07045012
- Volunteers
- 52 people
- Sponsor
- Beylikduzu State Hospital
Osteoporosis
Orthorexia Nervosa in Postmenopausal Osteoporosis
A total of 64 female patients diagnosed with osteoporosis based on dual-energy X-ray absorptiometry (DXA) measurements performed within the last six months, and 64 age-matched healthy controls without osteoporosis, will be…
- Trial name
- NCT06947213
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people
- Sponsor
- Beylikduzu State Hospital
Osteoporosis, Osteopenia
Serum Myostatin and Irisin Levels in Postmenopausal Women: Association With Bone Mineral Density and Muscle Strength
This study aims to evaluate the relationship between serum myostatin and irisin levels and bone mineral density and muscle strength in postmenopausal women.
- Trial name
- MYOIRISIN (NCT07519551)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Osteoperosis
The Investigation of the Effectiveness of Virtual Reality Applications in Postmenopausal Osteoporosis Patients
Osteoporosis is a progressive disease characterised by a decrease in bone mass, deterioration in bone microarchitecture, and increased fragility.
- Trial name
- NCT07231822
- Testing
- Conventional treatment, Virtual reality treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kirsehir Ahi Evran Universitesi
Calcium, Osteoporosis
A Study of Amorphous Calcium Carbonate in Postmenopausal Women
Using the FREEDOM substudy as a benchmark, evaluate the effects of amorphous calcium carbonate (ACC) on bone mineral density (BMD) in postmenopausal women, both with and without the combination of Denosumab treatment.
- Conditions
- Calcium, Osteoporosis, Bone Mineral Density, Bone Turnover Marker
- Trial name
- NCT06728462
- Testing
- Amorphous calcium carbonate
- Where
- Taiwan
- Volunteers
- 205 people
- Sponsor
- Universal Integrated Corp.
Osteoporosis, Postmenopausal Osteoporosis
Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility.
- Conditions
- Osteoporosis, Postmenopausal Osteoporosis, Frailty, Fragility Fractures
- Trial name
- LUMINOS (NCT07677072)
- Where
- Turkey (Türkiye)
- Volunteers
- 98 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Osteoporosis Risk, Osteoporosis, Postmenopausal
Evaluation of Osteo-Buddy in Improving Osteoporosis Knowledge
This is a pilot randomised controlled trial (RCT) to evaluate the use of a Virtual Health Assistant (VHA) named Osteo-Buddy in improving the knowledge of osteoporosis in older women.
- Trial name
- NCT07034131
- Testing
- Osteo-Buddy, Usual Care
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- SingHealth Polyclinics
Osteoporosis in Post-menopausal Women
Bone Health in Postmenopausal Women: The Effect of Exercise With or Without Medication for Osteoporosis
Osteoporosis is a systemic bone disorder characterised by a reduced bone mass and structural deterioration, increasing the risk of fragility fractures, particularly in women post-menopause.
- Trial name
- BEAT-OP (NCT07267325)
- Testing
- EXERCISE TRAINING, Antiresorptive medication (routine clinical care)
- Where
- United Kingdom
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Loughborough University
Menopausal Osteoporosis, Bone Markers
COMPASS - COpenhagen MenoPAuSe Study
During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to bone Loss and other complications.
- Trial name
- COMPASS (NCT07254429)
- Testing
- Triptorelin 11.25 mg, Sodium Chloride 0.9%, Estradiol (E2)
- Where
- Denmark
- Volunteers
- 192 people
- Sponsor
- Martin Blomberg Jensen
Postmenopausal Women With Osteoporosis at High Risk of Fracture
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.
- Trial name
- NCT07062978
- Testing
- QL1206, Prolia®
- Where
- China
- Volunteers
- 278 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Circadian Rhythm Disorders, Osteoporosis
Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal Osteoporosis
This is a randomized, controlled, and exploratory study designed to evaluate the chronotherapeutic effects of teriparatide administration in postmenopausal osteoporosis.
- Trial name
- NCT06951776
- Testing
- Morning administration group of teriparatide, Evening administration group of teriparatide
- Volunteers
- 28 people
- Sponsor
- Peking University Third Hospital
Osteoporosis, Postmenopausal, Osteoporotic Fractures
Evaluation of a Decision Analysis Model in the DASH-Osteo Decision Aid.
Fragility fractures, often caused by low bone mineral density, are a major health concern for postmenopausal women. One way to prevent these fractures is by taking medication, but deciding whether to start treatment can be…
- Conditions
- Osteoporosis, Postmenopausal, Osteoporotic Fractures, Diphosphonates, Fracture Risk Assessment
- Trial name
- DASH-Osteo (NCT07120854)
- Testing
- Decision aid with decision analysis model, Decision aid alone, Usual Care
- Where
- Spain
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Osteoporosis, Postmenopausal
Vascular Function, Sarcopenia and Pain in Postmenopausal Osteoporosis
This study aims to follow a cohort of osteoporotic patients treated with anti-osteoporotic drugs and to evaluate the impact of these treatments on the osteoporosis-cardiovascular-sarcopenia triad and on pain.
- Trial name
- VASCO (NCT05228262)
- Testing
- Cohort follow-up
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Clermont-Ferrand
Osteoporosis, Postmenopausal
Mechanisms of Anabolic Osteoporosis Therapy
The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.
- Trial name
- NCT05688969
- Testing
- early versus late biopsy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Postmenopausal Osteoporosis
AGE Burden and Response to Antiresorptive Therapy in Osteoporosis
Osteoporosis is a common condition that increases the risk of bone fractures. Although antiresorptive treatments such as bisphosphonates and denosumab are effective in increasing bone mineral density, some patients continue to…
- Trial name
- NCT07329543
- Volunteers
- 240 people
- Sponsor
- Bursa City Hospital
Osteoporosis, Postmenopausal
Effect of Postural Correction Exercises on Pelvic Floor Dysfunction in Postmenopausal Osteoporotic Women
This study aimed to investigate the effect of postural correction exercises on pelvic floor dysfunction in postmenopausal osteoporotic women
- Trial name
- NCT07806968
- Testing
- Estrogen replacement therapy, General advice, Postural correction exercise program
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Cairo University
Osteoporosis, Osteoporosis Postmenopausal
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of Denosumab, repeated for two years) versus a…
- Trial name
- NCT06938152
- Testing
- Romosozumab followed by Denosumab, Romosozumab and Denosumab Cycle Therapy
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- National Taiwan University Hospital
Female Osteoporosis
Female Osteoporosis
The aim of this study is to compare the Osteoporosis Risk Assessment Tool and the Osteoporosis Self-Assessment Tool with the gold standard DEXA in determining the risk of osteoporosis in the lumbar and femoral regions in female…
- Trial name
- OST and ORAI (NCT07402772)
- Volunteers
- 1,500 people
- Sponsor
- Kayseri City Hospital
Menopause, Perimenopausal Disorder
Virtual perI-/Menopause Registry of AusTrALia
13 million (50.7%) Australians are born with ovaries, 14% (~3 million) are currently aged 40-59 yrs, \& all such who live to midlife will experience menopause, defined as >12 months without a period.
- Conditions
- Menopause, Perimenopausal Disorder, Postmenopausal Symptoms, Health Knowledge, Attitudes, Practice
- Trial name
- VITAL (NCT06487130)
- Testing
- N/A Observational Registry
- Where
- Australia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Bespoke Clinical Research
Osteoporosis in Post-menopausal Women
Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures
The aim of this clinical trial is to investigate the effectiveness of romosozumab started without stopping denosumab in patients diagnosed with postmenopausal osteoporosis with a very high risk of fragility fractures and who is…
- Trial name
- MORD (NCT06720350)
- Testing
- Romosozumab and Denosumab Combination Therapy, Romosozumab Prefilled Syringe [Evenity], Denosumab (Prolia)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Marmara University